Connect with us

Spread & Containment

Best Genetics Stocks to Watch

These genetics stocks are quite advanced, both in the technology and desire to help people. These companies strive to use genetic editing to find cures.
The post Best Genetics Stocks to Watch appeared first on Investment U.

Published

on

Playing with genetics to form “better humans” is a science fiction fairy… Or is it? While these genetics stocks don’t strive to create The Human Race 2.0, they are quite advanced. Both in their technology and desire to help sick people.

These genetics stocks are companies that strive to use genetic editing to find cures. And the targeted diseases include cancer, those of the blood and others.

In addition, many of these disorders come from genetic mutations. So, these medical companies are finding ways to get rid of faulty genes and replace them with healthy ones.

You may be hesitant to invest in the companies I’ve outlined below.

But upon further inspection, you’ll find these companies have noble motivations.

Genetics Stocks to Buy

  1. Fulgent Genetics (Nasdaq: FLGT)
  2. Illumina (Nasdaq: ILMN)
  3. Editas Medicine (Nasdaq: EDIT)
  4. 23andMe (Nasdaq: ME)
  5. Beam Therapeutics Inc. (Nasdaq: BEAM)
  6. Graphite Bio Inc. (Nasdaq: GRPH)
  7. Caribou Biosciences Inc. (Nasdaq: CRBU)
  8. CRISPR Therapeutics AG (Nasdaq: CRSP)

Best Genetics Stocks

Fulgent Genetics

Market Cap: $2 billion

The first genetics stock to look at offers a variety of services. And these services help positively impact the everyday lives of people. Fulgent Genetics does this by using genetic testing.

For instance, tests that shed some light on rare diseases, genomes and parts of the cell. It’s clear they strive for high quality. Licenses and accreditations in seven states and associations are proof of that.

Additionally, the company offers COVID-19 testing on its website. Which I’m sure was a large source of income in the past two years. And it may even still provide a good chunk of change for them.

Fulgent strives to offer a wide variety of tests, and the most effective tests of anyone else.

Illumina

Market Cap: $55 billion

Illumina is a biotech company and genetics stock that’s focused on COVID-19.

In addition, it provides cancer solutions. Microbiology, Agri genomics and genetic and rare diseases. Those are all part of the menu of markets Illumina serves.

The company provides a wide array of testing, services and products. And its even using genetic sequencing to try and save a lemur population.

Recently, in November 2021, they partnered with a large investment firm. The firm’s called Sequoia Capital China. The alliance formed to support startups. Specifically, those who are making breakthroughs in the genetic scene.

Editas Medicine

Market Cap: $2 billion

Editas focuses on using CRISPR technology to fix broken genes. By doing this, they hope to create solutions for diseases. In particular, those that can be cured through genetic manipulation.

Early in November, Editas produced data for a cancer treatment. This data was preclinical, but it’s a great step in the right direction.

The company talks a lot about gene editing. Not in the sense that we are all flawed, and we could produce “better humans.” But in the sense that sometimes, diseases come from mutations in our DNA. And there may be a way to “edit” those mutated genes.

The hope is that in doing so, they can cure many of the disorders that ruin lives.

23andMe

Market Cap: $3 billion

This genetics stock began to investigate your ancestry. You order a kit, get it in the mail and then send them a DNA sample. 23andMe sends you back your results, and you get a look into your history, family and ancestors.

Further, the company provides services that tell you about your health. There are different kits you can buy. And each of the services gives different information about you.

Beam Therapeutics Inc.

Market Cap: $5 billion

Beam is a genetics stock that uses CRISPR technology. However, it differs from other companies a bit. It has figured out how to make edits to DNA and RNA without cutting any strands.

Beam also strives to create many medicines that directly influence DNA. With a handful of gene services, they are even able to make many different genetic edits all at the same time.

Graphite Bio Inc.

Market Cap: $557 million

Preclinical data is produced before testing can begin. Graphite has some preclinical data that shows they can cure sickle cell disease.

Graphite has an innate desire to help people with genetic diseases. And they focus on efficiency, too.

The name of this genetics stock is a reference to the breakthrough work of Dr. Rosalind Elsie Franklin, Ph.D.

She was the very first person to draw the structure of graphite. And in doing so, her research led to a much better understanding of DNA and RNA. And eventually, the illustration of those as well.

Caribou Biosciences Inc.

Market Cap: $1 billion

Caribou is in clinical stage, and it’s classified as a biopharma company. It’s home to those who’ve been paving the way with CRISPR technology. And Caribou focuses on helping people with cancer.

The leadership is strong and plentiful. And with over 14 licenses, it knows what it’s doing.

With two partnerships, the company is open to more. But the two partnerships it has now are with AbbVie and the Leukemia and Lymphoma Society.

Indeed, a great company run by great people.

Genetics Stocks: CRISPR Therapeutics AG

Market Cap: $5 billion

CRISPR focuses on coming up with solutions for blood diseases, diabetes and cancer. Along with other diseases, too.

This genetics stock has some great leadership, also. One of the co-founders even holds five patents for his own inventions.

In addition, CRISPR has several partnerships, including one with Bayer. Recently in November of 2021, they’ve begun clinical trials for Type 1 diabetes. And they are continuing to find solutions to more diseases.

“The Final Word” and Other Opportunities for Genetics Stocks

You may be a bit freaked out by talk of cherry-picking genes, and rightfully so. Who knows, maybe you’re excited by it.

As futuristic as that is, vanity doesn’t seem to be the focus of gene-editing businesses. It’s obvious they want to do what they can to get rid of these terrible disorders.

And for more insight on emerging trends and stocks to invest in, sign up for the Profit Trends e-letter below. It’s filled with tips and tricks on how to navigate the market straight from today’s leading trend experts.

The post Best Genetics Stocks to Watch appeared first on Investment U.

Read More

Continue Reading

Spread & Containment

VIRI: Enrollment Complete in FORTRESS Trial; Results Expected in September 2022…

By David Bautz, PhD
NASDAQ:VIRI
READ THE FULL VIRI RESEARCH REPORT
Business Update
FORTRESS Trial Fully Enrolled; Topline Results in September 2022
On…

Published

on

By David Bautz, PhD

NASDAQ:VIRI

READ THE FULL VIRI RESEARCH REPORT

Business Update

FORTRESS Trial Fully Enrolled; Topline Results in September 2022

On April 28, 2022, Virios Therapeutics, Inc. (NASDAQ: VIRI) announced that it has completed enrollment of 425 fibromyalgia patients into the Phase 2b FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of Herpes Simplex Virus-1) trial, a randomized, double blind, placebo controlled study of IMC-1. The primary endpoint of the trial is reduction in pain and secondary endpoints include change in fatigue, sleep disturbance, global health status, and patient functionality (NCT04748705). An outline of the trial is shown below.

In parallel with the FORTRESS trial, Virios is continuing the chronic toxicology studies of IMC-1 in two animal species. The results of these studies are required by regulators before Virios will be allowed to dose patients for one year or more, which is the plan for the Phase 3 program. The results of the chronic toxicology studies should be known around the time of the completion of the FORTRESS trial, thus the company should be able to move into a final Phase 3 program following completion of the current study, pending positive results.

Testing Combination Antiviral Therapy for the Treatment of Long COVID

In February 2022, Virios announced a collaboration with the Bateman Horne Center (BHC) to test combination antiviral therapy for the treatment of Long COVID. Following an infection with SARS-CoV-2, the virus that causes COVID-19, approximately 30% of patients will experience symptoms that last for weeks or months, which is referred to as Long COVID. The range of symptoms varies from patient to patient, however the most commonly reported (from a recent meta analysis) were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%) (Lopez-Leon et al., 2021).

The main theories for what might be causing ...

Full story available on Benzinga.com

Read More

Continue Reading

Spread & Containment

Type-I interferon stops immune system ‘going rogue’ during viral infections

Hamilton, ON (May 17, 2022) – McMaster University researchers have found not only how some viral infections cause severe tissue damage, but also how…

Published

on

Hamilton, ON (May 17, 2022) – McMaster University researchers have found not only how some viral infections cause severe tissue damage, but also how to reduce that damage.

Credit: Georgia Kirkos/McMaster University

Hamilton, ON (May 17, 2022) – McMaster University researchers have found not only how some viral infections cause severe tissue damage, but also how to reduce that damage.

 

They have discovered how Type I interferon (IFN) stops the immune system ‘going rogue’ and attacking the body’s own tissues when fighting viral infections, including COVID-19.

 

Their paper was published in the journal PLOS Pathogens today.

  

Senior author Ali Ashkar said IFN is a well-known anti-viral signalling molecule released by the body’s cells that can trigger a powerful immune response against harmful viruses.

 

“What we have found is that it is also critical to stop white blood cells from releasing protease enzymes, which can damage organ tissue. It has this unique dual function to kick start an immune response against a viral infection on the one hand, as well as restrain that same response to prevent significant bystander tissue damage on the other,” he said.

 

The research team investigated IFN’s ability to regulate a potentially dangerous immune response by testing it on both flu and the HSV-2 virus, a highly prevalent sexually transmitted pathogen, using mice. Data from COVID-19 patients in Germany, including post-mortem lung samples, was also used in the study.

 

“For many viral infections, it is not actually the virus that causes most of the tissue damage, it is our heightened immune activation towards the virus,” said Ashkar, a professor of medicine at McMaster.

  

First co-author of the study and PhD student Emily Feng said: “Our body’s immune response is trying to fight off the virus infection, but there’s a risk of damaging innocent healthy tissue in the process. IFNs regulates the immune response to only target tissues that are infected.

 

“By discovering the mechanisms the immune system uses that can inadvertently cause tissue damage, we can intervene during infection to prevent this damage and not necessarily have to wait until vaccines are developed to develop life-saving treatments,” she added.

 

“This applies not just to COVID-19, but also other highly infectious viruses such as flu and Ebola, which can cause tremendous and often life-threatening damage to the body’s organs,” said first study co-author Amanda Lee, a family medicine resident. 

 

Ashkar said the release of harmful proteases is the result of a ‘cytokine storm’, which is life-threatening inflammation sometimes triggered by viral infections. It has been a common cause of death in patients with COVID-19, but treatment has been developed to prevent and suppress the cytokine storm.

 

Ashkar said that steroids like dexamethasone are already used to rein in an extreme immune response to viral infections. The authors used doxycycline in their study, an antibiotic used for bacterial infections and as an anti-inflammatory agent, inhibits the function of proteases causing the bystander tissue damage.

 

Lee added: “This has the potential in the future to be used to alleviate virus-induced life-threatening inflammation and warrants further research.” 

 

The study was funded by the Canadian Institutes of Health Research.

 

-30-

 

Editors:

Pictures of Ali Ashkar and Emily Feng may be found at https://bit.ly/3wmSw0D

  

 

 


Read More

Continue Reading

Spread & Containment

mRNA vaccines like Pfizer and Moderna fare better against COVID-19 variants of concern

A comparison of four COVID-19 vaccinations shows that messenger RNA (mRNA) vaccines — Pfizer-BioNTech and Moderna — perform better against the World…

Published

on

A comparison of four COVID-19 vaccinations shows that messenger RNA (mRNA) vaccines — Pfizer-BioNTech and Moderna — perform better against the World Health Organization’s variants of concern (VOCs) than viral vector vaccines — AstraZeneca and J&J/Janssen. Although they all effectively prevent severe disease by VOCs, the research, publishing May 17th in the open access journal PLOS Medicine, suggests that people receiving a viral vector vaccine are more vulnerable to infection by new variants.

Credit: Carlos Reusser Monsalvez, Flickr (CC0, https://creativecommons.org/publicdomain/zero/1.0/)

A comparison of four COVID-19 vaccinations shows that messenger RNA (mRNA) vaccines — Pfizer-BioNTech and Moderna — perform better against the World Health Organization’s variants of concern (VOCs) than viral vector vaccines — AstraZeneca and J&J/Janssen. Although they all effectively prevent severe disease by VOCs, the research, publishing May 17th in the open access journal PLOS Medicine, suggests that people receiving a viral vector vaccine are more vulnerable to infection by new variants.

By March 2022, COVID-19 had caused over 450 million confirmed infections and six million reported deaths. The first vaccines approved in the US and Europe that protect against serious infection are Pfizer-BioNTech and Moderna, which deliver genetic code, known as mRNA, to the bodies’ cells, whereas Oxford/AstraZeneca and J&J/Janssen are viral vector vaccines that use a modified version of a different virus — a vector — to deliver instructions to our cells. Three vaccines are delivered as two separate injections a few weeks apart, and J&J/Janssen as a single dose.

Marit J. van Gils at the University of Amsterdam, Netherlands, and colleagues, took blood samples from 165 healthcare workers, three and four weeks after first and second vaccination respectively, and for J&J/Janssen at four to five and eight weeks after vaccination. Samples were collected before, and four weeks after a Pfizer-BioNTech booster.

Four weeks after the initial two doses, antibody responses to the original SARS-CoV-2 viral strain were highest in recipients of Moderna, followed closely by Pfizer-BioNTech, and were substantially lower in those who received viral vector vaccines. Tested against the VOCs – Alpha, Beta, Gamma, Delta and Omicron – neutralizing antibodies were higher in the mRNA vaccine recipients compared to those who had viral vector vaccines. The ability to neutralize VOCs was reduced in all vaccine groups, with the greatest reduction against Omicron. The Pfizer-BioNTech booster increased antibody responses in all groups with substantial improvement against VOCs, including Omicron.

The researchers caution that their AstraZeneca group was significantly older, because of safety concerns for the vaccine in younger age groups. As immune responses tend to weaken with age, this could affect the results. This group was also smaller because the Dutch government halted use for a period.

van Gils concludes, “Four COVID-19 vaccines induce substantially different antibody responses.”

#####

In your coverage, please use this URL to provide access to the freely available paper in PLOS Medicine:

http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003991

Citation: van Gils MJ, Lavell A, van der Straten K, Appelman B, Bontjer I, Poniman M, et al. (2022) Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. PLoS Med 19(5): e1003991. https://doi.org/10.1371/journal.pmed.1003991

 

Author Countries: The Netherlands, United States

 

Funding: This work was supported by the Netherlands Organization for Scientific Research (NWO) ZonMw (Vici grant no. 91818627 to R.W.S., S3 study, grant agreement no. 10430022010023 to M.K.B.; RECoVERED, grant agreement no. 10150062010002 to M.D.d.J.), by the Bill & Melinda Gates Foundation (grant no. INV002022 and INV008818 to R.W.S. and INV-024617 to M.J.v.G.), by Amsterdam UMC through the AMC Fellowship (to M.J.v.G.) and the Corona Research Fund (to M.K.B.), and by the European Union’s Horizon 2020 program (RECoVER, grant no. 101003589 to M.D.d.J). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


Read More

Continue Reading

Trending